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Background: Hyperglycemia leads to cardiac oxidative stress and an imbalance in glucose homeostasis. Diabetic
cardiomyopathy is characterised by cardiac hypertrophy and fibrosis. However, the underlying mechanisms of
diabetic cardiomyopathy are not fully understood. This study aimed to investigate the effects of alpha-lipoic acid
(ALA) on cardiac energy metabolism, antioxidant effect, and fibrosis in the hearts of Otsuka Long-Evans Tokushima
fatty (OLETF) rats.
Methods: Animals were separated into non-diabetic Long-Evans Tokushima Otsuka (LETO) rats and diabetes-prone
OLETF rats with or without ALA (200 mg/kg/day) administration for 16 weeks. Diabetic cardiomyopathy was
assessed by staining with Sirius Red. The effect of ALA on AMPK signalling, antioxidant enzymes, and fibrosis-related
genes in the heart of OLETF rats were performed by Western blot analysis or immunohistochemistry.
Results: Western blot analysis showed that cardiac adenosine monophosphate-activated kinase (AMPK) signalling
was lower in OLETF rats than in LETO rats, and that ALA treatment increased the signalling in OLETF rats.
Furthermore, the low antioxidant activity in OLETF rats was increased by ALA treatment. In addition to increased
Sirius red staining of collagen deposits, transforming growth factor-β1 (TGF-β1) and connective tissue growth factor
(CTGF) were expressed at higher levels in OLETF rat hearts than in LETO rat hearts, and the levels of these factors
were decreased by ALA.
Conclusions: ALA enhances AMPK signalling, antioxidant, and antifibrogenic effect. Theses findings suggest that
ALA may have beneficial effects in the treatment of diabetic cardiomyopathy.
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A constant rate of mitochondrial ATP synthesis and glu-
cose uptake is necessary for the heart to continually con-
tract [1]. Dysregulation of cardiac energy metabolism and
insulin resistance causes morphological alterations in the
myocardium [2]. In particular, previous studies have
shown that perivascular and/or interstitial fibrosis are the
most prominent myocardial structural changes in diabetic
patients [3]. Despite the known relationship between en-
ergy metabolism and insulin resistance in the diabetic
heart, the mechanism underlying the development of dia-
betic cardiomyopathy remains to be elucidated.* Correspondence: anaroh@gnu.ac.kr
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reproduction in any medium, provided the orAdiponectin is an adipokine that has anti-diabetic and
anti-atherogenic effects [4]. Hypoadiponectinemia leads
to cardiac oxidative stress and dysregulation of glucose
homeostasis [5]. Adiponectin is also synthesized and
secreted by human and murine cardiomyocytes [6]. Adi-
ponectin in insulin resistance correlates with activation
of the adenosine monophosphate-activated kinase
(AMPK) signalling pathway, which is implicated in fatty
acid oxidation and glucose uptake. AMPK is a metabolic
stress sensor or effector that controls energy homeosta-
sis in the cell. AMPK is phosphorylated and activated by
liver kinase B1 (LKB1) in response to an increase in the
AMP/ATP ratio [7]. Activated AMPK phosphorylates
and inactivates acetyl coenzyme A carboxylase (ACC),
which is involved in fatty acid oxidation [8]. In
adiponectin-deficient mice, diminished AMPK signalling. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trophy [9].
Dysfunctional AMPK activity decreases antioxidant
gene expression and induces inflammation and the pro-
duction of oxidants [10]. An overabundance of oxidants
is closely associated with insulin resistance. Overproduc-
tion of reactive oxygen species (ROS) is induced by
hyperglycemia, dyslipidemia, advanced glycation end-
products (AGEs), and lipid peroxides [11]. In particular,
ROS production in mitochondria is increased in the dia-
betic heart, resulting in reduced cardiac energy metabol-
ism [12].
Alpha-lipoic acid (ALA) was originally identified as an
obligatory cofactor for mitochondrial α-ketoacid dehy-
drogenases and was found to play an important role in
mitochondrial energy metabolism [13]. ALA enhances
glucose utilization in isolated rat hearts [14]. Growing
evidence suggests that ALA maintains the cellular anti-
oxidant status by either enhancing or inducing the up-
take of antioxidant enzymes [15]. ALA administration
reduces aortic AGEs content, cardiac mitochondrial
superoxide production, and insulin resistance in diabetic
animal models [16].
Therefore, the purpose of this study was to investigate
the effects of dietary ALA administration on the AMPK
signalling pathway and on ROS associated with the de-
velopment and progression of diabetic cardiomyopathy.
Materials and methods
Animals
Diabetes-prone male Otsuka Long-Evans Tokushima
fatty (OLETF) rats (4 weeks old) and non-diabetic con-
trol Long-Evans Tokushima Otsuka (LETO) rats were
obtained from the Otsuka Pharmaceutical Company
(Tokushima, Japan) and maintained in the animal facility
at Gyeongsang National University (Republic of Korea).
All experiments were performed in accordance with the
National Institutes of Health Guidelines on the Use of
Laboratory Animals. The University Animal Care Com-
mittee for Animal Research of Gyeongsang National
University approved the study protocol. LETO and
OLETF rats were housed individually with an alternating
12-h light/dark cycle. OLETF rats (aged 12 weeks) were
randomly separated into two groups (n = 9–10 per
group) and were fed standard chow with or without
ALA (200 mg/kg/day, Bukwang Pharmaceutical Com-
pany, Seoul, South Korea) for 16 weeks. LETO rats were
fed standard chow without ALA. All rats were weighed
immediately before sacrifice at 28 weeks of age.
Tissue collection and sample preparation
For tissue analysis, rats were anesthetized with Zoletil
(5 mg/kg, Virbac Laboratories, Carros, France) and then
perfused transcardially with heparinized saline followedby 4% paraformaldehyde in 0.1 M phosphate buffered
saline (PBS). The hearts were fixed with the same re-
agent for 12 h at 4°C. The samples were then processed
for paraffin embedding, and 5 μm-thick sections were
cut. Sections were stained with hematoxylin and eosin
(H&E). The sections were visualized under a BX51 light
microscope (Olympus, Tokyo, Japan), and digital images
were captured and documented.
Sirius red staining
Sirius red staining is commonly used to identify col-
lagens. To determine cardiac collagen accumulation,
deparaffinized heart sections were stained with Weigert’s
hematoxylin (Sigma-Aldrich, MO, USA) for 8 min,
washed, and restained with picro-sirius red (Sigma) for 1
h and washed. Sections were dehydrated through graded
alcohols, cleared in xylene, covered with a coverslip, and
sealed with Permount (Sigma).
Sircol collagen assay
The Sircol collagen assay is a dye-binding method
designed for the analysis of acid and pepsin-soluble col-
lagens, which are newly synthesized during inflammation
and wound healing. The heart tissues were frozen in li-
quid nitrogen and stored at -80°C prior to the assay. The
collagen concentration was analysed using a Sircol assay
kit (Bioclor Ltd., Northern Ireland, UK) according to the
instructions provided by the manufacturer. A standard
curve was derived and the collagen content of the sam-
ple was calculated.
Immunohistochemistry
Deparaffinized heart sections were placed in a solution
of 0.3% H2O2 for 10 min. After washing, sections were
treated with diluted blocking goat serum for 20 min.
Slides were incubated overnight at 4°C in a humidified
chamber with anti-mouse-Cu/Zn-superoxide dismutase
(SOD) (1:100, Santa Cruz Biotechnology, USA) diluted
in blocking serum. After washing three times with 0.1 M
PBS, sections were incubated for 1 h at room
temperature with a secondary antibody (1:200). After
washing, sections were incubated in avidin-biotin-
peroxidase complex solution (ABC solution, Vector
Laboratories, Burlingame, CA, USA). Sections were
developed with 0.05% diaminobenzidine (DAB, Sigma)
containing 0.05% H2O2 and were dehydrated through
graded alcohols, cleared in xylene, covered with a cover-
slip, and sealed with Permount (Sigma). Sections were
visualized under a BX51 light microscope (Olympus).
For immunostaining of collagen tissue growth factor
(CTGF), heart sections were incubated with the rabbit
anti-rat CTGF (1:500, Abcam, Cambridge, MA, USA)
overnight at 4°C. Sections were incubated with Alexa-
Fluor 594-conjugated donkey anti-rabbit antibody
Table 1 Body and heart weight in OLETF rats with or
without ALA treatment
LETO OLETF OLETF + ALA
Body weight (g) 538.55 ± 8.63 636.40 ± 15.55* 518.54 ± 14.92†
Heart weight (g) 1.36 ± 0.03 1.52 ± 0.02* 1.43 ± 0.03†
Heart/body weight
(ratio)
2.73 ± 0.05 2.52 ± 0.09* 3.05 ± 0.05†
Significance: *P < 0.05. vs. LETO rats, †P < 0.05. vs. OLETF rats.
Lee et al. Cardiovascular Diabetology 2012, 11:111 Page 3 of 10
http://www.cardiab.com/content/11/1/111(1:1,000, Invitrogen, Carlsbad, CA, USA). Fluorescence
was visualized under a confocal microscope (FV-1000,
Olympus).
Cytosolic and nuclear fraction
For cytosolic and nuclear fractions, the hearts were
promptly excised and placed in ice-cold PBS. After
chopping in ice-cold lysis buffer (10 mM HEPES-KOH
[pH7.9], 1.5 mM MgCl2, 10 mM KCl, 1 μg/ml aprotinin,
3 μg/ml pepstatin, 0.5 μg/ml leupeptin, 0.2 mM PMSF,
0.5 mM DTT), the hearts were homogenized. The frac-
tions of heart were prepared according to Andrews and
Faller [17].
Membrane fractionation
The hearts were promptly excised and placed in ice-cold
PBS. After chopping in ice-cold hypertonic lysis buffer
(10 mM Tris, 10 mM NaCl, 3 mM MgCl2, 1 mM so-
dium vanadate, 5 μg/ml aprotinin, 3 μg/ml pepstatin,
5 μg/ml leupeptin, 1 mM EDTA, 1mM DTT), the hearts
were homogenized. Homogenates were centrifuged at
12,500 × g for 15 min. The resulting pellet were resus-
pended in 1% Triton lysis buffer and centrifuged at
12,500 × g for 15 min.
Western blot analysis
For total heart extracts, frozen hearts were homogenized
in a T-PER tissue protein extraction reagent (Thermo
scientitic, IL, USA) containing Halt protease inhibitor
cocktail (Thermo scientitic). The following antibodies
were used: LKB1 (Wako Pure Chemical Company,
Osaka, Japan); phospho-AMPK, AMPK, phospho-acetyl-
CoA carboxylase (ACC), ACC, Sterol regulatory
element-binding protein-1 (SREBP-1, BD Biosciences,
CA, USA), glucose transporter 4 (GLUT4, Cell Signaling
Technology, Danvers, MA, USA), receptor for advanced
glycosylation end products (RAGE), heme oxygenase-1
(HO-1), Cu/Zn-SOD, and transforming growth factor-β1
(TGF-β1) (all from Santa Cruz Biotechnology). The
membranes were probed with each antibody or α-tubulin
antibody (Sigma) and visualized using an enhanced
chemiluminescence substrate (Pierce, Rockford, IL,
USA). The Multi-Gauge V 3.0 image analysis program
(Fujifilm, Tokyo, Japan) was used to measure band
density.
Statistical analysis
Differences between LETO, OLETF, and OLETF rats fol-
lowing ALA administration were determined with one-
way ANOVA, followed by Bonferroni post-hoc analysis.
Values are expressed as the mean ± standard error of
the mean (SEM). A p value < 0.05 was considered statis-
tically significant.Results
Effect of ALA on heart and body weight of OLETF rats
OLETF rats were fed ALA for 16 weeks. Without ALA
treatment, the body weight of OLETF rats at 28 weeks
was significantly higher than that of LETO rats (p < 0.05)
(Table 1). However, ALA caused a significant reduction
in the body weight of OLETF rats (p < 0.05). Whole
heart weights were measured at the time of sacrifice,
and the heart/body weight ratio was calculated for each
group. Although OLETF heart weights were higher than
those of LETO rats, the heart/body weight ratio was sig-
nificantly lower in OLETF rats without ALA treatment
than in OLETF rats with ALA treatment (p < 0.05).Effect of ALA on cardiac AMPK signalling pathway in
OLETF rats
To determine the effect of ALA on cardiac LKB1 expres-
sion, Western blot analysis was performed (Figure 1A).
Levels of cardiac LKB1 expression were significantly
lower in OLETF rats than in LETO rats (p < 0.05). How-
ever, ALA significantly increased LKB1 expression in
OLETF rats (p < 0.05). The effects of ALA on the phos-
phorylation of AMPK and ACC expression were then
evaluated (Figure 1B). Western blot analysis showed that
the levels of cardiac phospho (p)-AMPK and p-ACC in
OLETF rats were lower than in LETO rats and that they
increased after ALA administration (p < 0.05). To investi-
gate the dynamics of the downstream AMPK signalling
pathways in the heart, Western blot analysis of SREBP1
and GLUT4 expression was performed (Figure 1C and
D). Compared with LETO rats, western blot revealed that
there is an increase of precursor segment of SREBP-1
expression in both total and cytosolic lysates OLETF
rats approximately to 1.42 and 4.51 times, respectively
(Figure 1C). Also, mature segment of SREBP-1 was
increased in OLETF rats compared with LETO rats.
However, ALA treatment attenuated SREBP-1 expression
in total and nuclear lysates from the heart of OLETF rats
(1.24 and 2.76 times, respectively, p < 0.05). In the heart
tissues, the GLUT4 levels in all the lysates were
decreased in OLETF rats compared with LETO rats
(Figure 1D). ALA treatment increased GLUT4 transloca-
tion from intracellular sites to the plasma membrane.
Figure 1 Effect of ALA on the cardiac AMPK signalling pathway in OLETF rats. (A) Representative Western blots of LKB1. Quantification of
cardiac LKB1 by Western blot analysis. (B) Western blot showing total (T) and phosphorylated (p) forms of AMPK and ACC in the hearts from each
group. Quantification of the phosphorylation of each protein on Western blots. The densitometry value for each phospho-protein was normalized
against total protein and the values are presented as arbitrary units (A.U.). Data are presented as the mean ± SEM. *p < 0.05 vs. LETO rats; †p <
0.05 vs. OLETF rats. (C) A Western blot showing the level of cardiac SREBP1 in each group. The total, cytosolic, and nuclear lysates were prepared
from heart tissues. a-tubulin and lamin A were used as the control to verify identical protein loading. (D) A western blot showing the level of
cardiac GLUT4 in each group. The total lysate, plasma membrane, and post-plasma membrane fraction were prepared from heart tissues.
a-tubulin and Ponceau S dye staining was used as the control to verify identical protein loading.
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The effect of ALA on cardiac RAGE expression was
evaluated in OLETF rats by Western blot analysis
(Figure 2A). Cardiac RAGE expression was significantly
higher in OLETF rats than in LETO rats, and ALA sig-
nificantly decreased RAGE expression in OLETF rats
(p < 0.05) (Figure 2B).
Effect of ALA on cardiac HO-1 and Cu/Zn-SOD expression
in OLETF rats
To investigate the effect of ALA on antioxidant enzyme
activity in response to oxidative stress in OLETF rat
hearts, Western blot analysis of HO-1 and Cu/Zn-SOD
expression and immunohistochemistry of Cu/Zn-SOD
were performed (Figure 3). Western blot analysis
revealed that cardiac HO-1 and Cu/Zn-SOD expression
levels were significantly lower in OLETF rats than in
LETO rats (Figure 3A and B). However, the expressionof both proteins was significantly increased in OLETF
rats by ALA treatment (p < 0.05). Immunohistochemistry
showed that Cu/Zn-SOD-positive cells were distributed
throughout the cardiomyocytes of LETO rats and
OLETF rats with ALA treatment (Figure 3C). However,
without ALA treatment, Cu/Zn-SOD-positive cells were
stained more weakly in OLETF rats.
Effect of ALA on collagen accumulation in OLETF rat
hearts
To examine the effects of ALA on cardiac morphology
in 28-week-old OLETF rats, H&E staining was per-
formed (Figure 4A). No significant morphological
changes were observed between LETO and OLETF rats.
Sirius red-stained collagen deposits were observed in the
left ventricles (LV) of OLETF rat hearts (Figure 4B and
C). However, ALA treatment reduced Sirius red-stained
collagen deposition. The effect of ALA on collagen
Figure 2 Effect of ALA on cardiac RAGE expression in OLETF
rats. (A) Western blot showing the level of cardiac RAGE in each
group. (B) Quantification of cardiac RAGE by Western blot analysis.
Densitometry values of RAGE protein were normalized to that of α-
tubulin and are presented as arbitrary units (A.U.) relative to LETO
expression levels. Data are presented as the mean ± SEM. *p < 0.05
vs. LETO rats; †p < 0.05 vs. OLETF rats.
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Sircol collagen assay (Figure 4D). As observed with Sir-
ius red staining, OLETF rats had significantly more sol-
uble collagen than LETO rats (p < 0.05). After ALA
administration, a significant decrease in the quantity of
collagen was observed (p < 0.05).
Effect of ALA on TGF-β1 and CTGF expression in OLETF
rat hearts
The effect of ALA on cardiac TGF-β1 and CTGF ex-
pression was evaluated in OLETF rats by Western
blot and immunofluorescence analyses, respectively
(Figure 5). Cardiac TGF-β1 expression was significantly
higher in OLETF rats than in LETO rats (p < 0.05), and
ALA treatment significantly decreased TGF-β1 expres-
sion in OLETF rats (p < 0.05) (Figure 5A and B).
CTGF-positive cells were distributed throughout the
cardiomyocytes in OLETF rats (Figure 5C). However,
CTGF staining was weak in LETO rats and OLETF
rats treated with ALA.
Discussion
The results of this study demonstrate that ALA sti-
mulates the AMPK signalling pathway and attenuates
cardiac fibrosis in OLETF rats. ALA increasedphosphorylation of AMPK and ACC, decreased
SREBP-1, and increased GLUT4 translocation in the
hearts of OLETF rats. Furthermore, ALA decreased
RAGE, TGF-β1, and CTGF expression by increasing
the activity of antioxidant enzymes, such as HO-1 and
Cu/Zn-SOD. Thus, the finding that ALA attenuates
collagen accumulation in the heart of diabetes-prone
OLETF rats by improving cardiac lipid metabolism
and antioxidant activity indicates that chronic dietary
administration of ALA to pre-diabetic OLETF rats
could prevent diabetic cardiomyopathy.
A previous study showed that high dose of ALA
reduces body weight in obese humans [18], ALA treat-
ment is associated with body fat loss, which it mediates
by suppressing AMPK activity in the hypothalamus
[19]. This effect was attributed to the appetite-
suppressing properties of ALA and to increased energy
expenditure. However, the mechanism by which ALA
induces body weight loss is poorly understood. In
streptozotocin (STZ)-induced animal model, ALA did
not attenuate the weight loss in control rats [20]. Previ-
ous studies showed that 180 mg/kg/day of 24-months
ALA supplementation in Sprague-Dawley rats showed
no serious adverse effects in hematology, biochemistry,
organ gross pathology, and neoplasm [21]. Thus, our
study did not contain ALA-treated LETO rats. Al-
though recent scientific studies emphasizes that obesity
is major risk factor for diabetic cardiomyopathy, the re-
lationship between obesity and heart function is not
completely known. However, pharmacologic strategies
for contribution of weight loss and prevention of
weight gain are reported [22,23]. Recent report showed
that impaired left ventricular ejection fraction (LVEF),
enhanced LV remodeling, inflammation, and fibrosis
were reversed by obesity reduction in obese mice [24].
These findings suggested the important role of obesity
in tissue damage to the myocardium other than those
related to diabetic coronary artery diseases. In addition,
myocardial apoptosis, fibrosis, and anti-oxidant biomar-
kers in LV myocardium were significantly suppressed
in obese mice and reversed in obese mice after reduc-
tion of body weight. In our study, ALA treatment sig-
nificantly attenuated heart and body weight in OLETF
rats. Although the heart weight of OLETF rats was
higher than that of LETO rats, the heart to body
weight ratio was not increased. This does not necessar-
ily mean that a high heart weight is closely associated
with diabetic cardiac hypertrophy. ALA could have sig-
nificantly contributed to the reduction in body weight
with affecting cardiac inflammation and fibrosis in this
pre-diabetic animal model. Thus, our findings suggest
that pharmacological treatment could at least partially
support why diabetic cardiomyopathy was enhanced
after weight reduction.
Figure 3 Effect of ALA on cardiac HO-1 and Cu/Zn-SOD expression in OLETF rats. (A) Western blot showing the level of cardiac HO-1 in
each group. Quantification of cardiac HO-1 by Western blot analysis. (B) Western blot showing the level of cardiac Cu/Zn-SOD in each group.
Quantification of cardiac Cu/Zn-SOD by Western blot analysis. The densitometry value of each protein was normalized to that of α-tubulin and
the values are presented as arbitrary units (A.U.) relative to LETO expression levels. Data are presented as the mean ± SEM. *p < 0.05 vs. LETO rats;
†p < 0.05 vs. OLETF rats. (C) Representative micrographs of immunostained cardiac Cu/Zn-SOD in each group. Scale bar = 100 μm.
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signalling pathways in the diabetic heart
Adiponectin increases insulin sensitivity by increasing fatty
acid oxidation, resulting in reduced circulating fatty acid
levels and reduced triglyceride (TG) content in muscle [25].
Energy homeostasis is vital for continuous cardiac pumping
activity, and adiponectin controls energy homeostasis by
modifying through glucose uptake [26]. In our previous
studies, serum adiponectin was shown to be expressed at
lower levels in OLETF rats than in LETO rats, and ALA
increased adiponectin levels in OLETF rats. [27]. AMPK is
phosphorylated and activated by its upstream kinase, LKB1,
and both are conserved serine/threonine kinases that regu-
late metabolism [28]. In this study, diabetes-prone OLETF
rats had low cardiac LKB1 expression, which was increased
by ALA administration. This result is consistent with the
report that obese insulin-resistant Zucker rats have
decreased LKB1 content in muscle [29]. Moreover, the
lower expression of LKB1 in the heart correlated closely
with lower AMPK/ACC signalling pathway activity. These
results support a role for ALA in promoting the effects of
SIRT1 activation and LKB1-AMPK signalling on insulin
sensitivity [30,31]. SREBP1, which is negatively regulatedby AMPK, is a major regulator of fatty acid synthesis
[32]. Consistent with the observation that AMPK inhibits
lipogenesis by reducing SREBP1 expression and by acti-
vating glucose uptake via GLUT4 upregulation [27,33],
ALA reversed the increase in the levels of SREBP1 and
decreased the levels of GLUT4 in OLETF rat hearts. In
our previous study, we also confirmed the effect of ALA
on SREBP1 and GLUT4 expression in non-alcoholic fatty
liver disease of OLETF rats [27]. SREBP1 expression is
significantly higher in nonalcoholic fatty liver disease
than in control animals [34]. ALA reduces circulating
free fatty acids (FFA) and TG levels by reducing lipid ac-
cumulation in non-adipose tissue as well as in adipose
tissue [27,35]. In addition, our study confirms that ALA
may contribute to inhibit the proteolytic cleavage and
nuclear translocation of SREBP-1 in the heart of diabetic
OLETF rats. This finding is in agreement with the
results reported by Hao et al. [36] that high glucose in-
crease lipogenesis by increasing precursor and mature
(cleaved form) segment of SREBP-1 in renal tubular cells
and HKC cells. The roles of cardiac glucose uptake and
insulin action have been demonstrated in mice with
cardiac-specific ablation of GLUT4, which developed
Figure 4 Effect of ALA on cardiac collagen deposition in OLETF rats. Representative micrographs of H&E-stained (A) and Sirius red-stained
(B) heart sections from each group. The black lined-box (in B) shows a high-magnification micrograph (C) of Sirius red-stained sections. Scale
bar = 1000 μm (200 μm in C). (D) Sircol collagen assay quantifying soluble collagen in the hearts of LETO and OLETF rats with or without ALA.
Data are presented as the mean ± SEM. *p < 0.05 vs. LETO rats; †p < 0.05 vs. OLETF rats.
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[37]. In OLETF rats, caloric restriction improves insulin
resistance in association with increased adipocyte-specific
GLUT4 expression. It has been reported that impairment
of glucose uptake in obesity is closely associated with the
reduction of cellular GLUT4 content and translocation
into plasma membrane [38,39]. Our study shows that
the protein expression of both total lysates and plasma
membrane is decreased, indicating that glucose metabol-
ism would be reduced in the heart of OLETF rats. How-
ever, ALA enhanced cellular GLUT4 contents and
translocation. This finding is in agreement with the
results reported by Park et al. [38] and Guo et al. [33]
that caloric restriction or telmisartan reduces insulinresistance by improving GLUT4 gene expression and
GLUT4 translocation to the plasma membrane. Penu-
mathsa et al. [40] also demonstrated that the antioxidant
resveratrol enhances GLUT4 translocation in the STZ-
induced diabetic heart. This suggests that obesity-induced
cardiac dysfunction may be attributable to chronic altera-
tions in cardiac glucose and lipid metabolism and in the
levels of circulating adipokines, including adiponectin.
ALA has antioxidant and anti-inflammatory effects in the
diabetic heart
In addition to cardiac dysfunction caused by energy
disturbances and oxidative stress, an association be-
tween the deleterious effects of AGEs and diabetic
Figure 5 Effect of ALA on cardiac TGF-β1 and CTGF expression in OLETF rats. (A) A Western blot showing the level of cardiac TGF-β1 in
each group. (B) Quantification of cardiac TGF-β1 by Western blot analysis. The densitometry value of each protein was normalized to that of α-
tubulin and the values are presented as arbitrary units (A.U.) relative to LETO expression levels. Data are presented as the mean ± SEM. *p < 0.05
vs. LETO rats; †p < 0.05 vs. OLETF rats. (C) Representative micrographs of immunostained CTGF in the hearts from each group. Scale bar = 100 μm.
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human studies [41]. Kuhla et al. [42] suggested that
targeting the AGE/RAGE interaction with an inhibitor
of RAGE may be of therapeutic value in oxida-
tive stress-induced hepatic inflammation. Our results
showed that ALA inhibited increased cardiac RAGE ex-
pression in OLETF rats. These data indicate that the
oxidative stress-dependent AGE/RAGE interaction may
be regulated by the antioxidant ALA. In this study,
ALA increased the antioxidant activity in OLETF rats.
Ogborne et al. [43] first reported that ALA increases
HO-1 expression in human monocytic THP-1 cells. In
Zucker diabetic fat rats, upregulation of HO-1 activity
induced by protoporphyrin increased adiponectin levels
and improved insulin sensitivity by increasing AMPK
phosphorylation, and decreased adipose tissue volumes
[44]. In addition to HO-1 expression, Cu/Zn-SOD
expression, which was reduced in OLETF rat hearts,
was increased by ALA treatment. The downregulation
of antioxidant enzymes, including HO-1 and Cu/Zn-
SOD, under conditions of chronic obesity or insulin
resistance-induced oxidative stress, may promote the
progression of diabetic cardiomyopathy.
ALA has antifibrogenic effects in the diabetic
cardiomyopathy
Diabetes-induced cardiac fibrosis is a major risk factor
for the progression of diabetic cardiomyopathy, whichcan result in cardiac cell death, fibrosis, and endothelial
dysfunction [45,46]. Guo et al. [6] demonstrated that
decreased plasma adiponectin levels may contribute to
myocardial hypertrophy in STZ-induced diabetic rats.
Furthermore, adiponectin supplementation improved
concentric cardiac hypertrophy in adiponectin-deficient
mice [9]. Recent study showed that recombinant human
granulocyte-colony stimulating factor (G-CSF) amelio-
rates cardiac diastolic dysfunction and fibrosis in OLETF
rats [47]. Although cardiac hypertrophy was not
detected in the OLETF rat model used in this study, re-
cent study showed that ALA (100 mg/kg/day) reversed
impairment of systolic function in STZ-treated diabetic
rats compared to controls [21]. Indeed, diabetic heart
disease is associated with increased interstitial fibrosis,
which is caused by collagen accumulation via an increase
in the level of type III collagen [48]. Consistent with the
observation that ALA ameliorates cardiac fibrosis in
STZ-induced diabetes [20], Sirius red staining also
showed that ALA inhibited collagen accumulation in
marginal regions between the right and left ventricles in
OLETF rat hearts. Thus this data suggest that compar-
ing STZ-induced diabetic rats, diabetes prone-OLETF
rats induce mild diabetic cardiomyopathy. TGF-β1 is a
key factor in the formation of fibrosis, which results
from collagen deposition. During cardiac pathology,
TGF-β1 is expressed at high levels in the heart [49].
CTGF, which is a potent profibrotic factor, induces the
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blasts in response to TGF-β1 [50]. Western blot analysis
of TGF-β1 expression and immunofluorescence analysis
of CTGF expression showed that CTGF-positive cell
number was reduced by ALA treatment. Our results
support the hypothesis that hyperglycemia induces
changes in cardiac structure via the generation of AGEs
and ROS, and via TGF-β1 stimulation [51].
Conclusion
Collectively, these data demonstrate that ALA enhances
the AMPK/ACC/SREBP1/GLUT4 signalling pathway,
inhibits RAGE expression, reduces oxidative stress, and
prevents myocardial fibrosis in OLETF rats. Thus, this
study suggests that hyperglycemia and obesity exacer-
bate diabetic cardiomyopathy by inducing cardiac fibro-
sis and dysregulation of energy homeostasis.
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